Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$11.48 USD
+0.04 (0.35%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Zevra Therapeutics, Inc. has a market cap of $625.53M, which represents its share price of $11.44 multiplied by its outstanding shares number of 54.68M. As a small-cap company, ZVRA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ZVRA 11.48 +0.04(0.35%)
Will ZVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Other News for ZVRA
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference | ZVRA ...
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call | ZVRA Stock News
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to ...
ZVRA: Zevra Therapeutics Seeks EMA Approval for NPC Drug Arimoclomol
Zevra Therapeutics submits MAA to EMA for evaluation of arimoclomol